Tech Company Inital Public Offerings
Atea Pharmaceuticals IPO
Atea Pharmaceuticals was bought by . Atea Pharmaceuticals shares started trading on 10/29/2020.
Transaction Overview
Company Name
Announced On
10/29/2020
Transaction Type
IPO
Amount
$300,000,000
Proceeds Purpose
We currently anticipate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of AT-527 for the treatment of moderate COVID-19, AT-787 for the treatment of chronic HCV, AT-752 for the treatment of dengue, our RSV program, and the remainder, if any, for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
125 Summer St.
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Not Recorded
Overview
Discovering and rapidly advancing transformative antiviral therapies. Atea (Nasdaq: AVIR) is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/29/2020: Honor Technology venture capital transaction
Next: 10/29/2020: Odaseva venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs